FDA approves Bristol Myers Squibb's Camzyos for pediatric oHCM

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. TSLA
9. GOOGL
10. BRZE

Go back to FDA approves Bristol Myers Squibb's Camzyos for pediatric oHCM

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Ad

September 30, 2026 5:32 PM EDT

CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric population

Approval based on positive results of Phase 3 SCOUT-HCM trial, building on the extensive clinical evidence for CAMZYOS in adults with oHCM

PRINCETON, N.J.--(BUSINESS... More